Aligos Therapeutics Inc. (ALGS) NASDAQ
$0.98 (0.04) (-4.02%)
Market Cap: $74.08M
As of 03/27/24 04:00 PM EDT. Market closed.
Aligos Therapeutics Inc. (ALGS)
NASDAQ
$0.98
(0.04) (-4.02%)
Market Cap: $74.08M
As of 03/27/24 04:00 PM EDT. Market closed.
aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, ... read more
aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-ã? agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california. read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Nuechterlein Carole | Director | Oct 25, 2023 | Buy | $0.76 | 7,933,601 | 6,004,149 | 11,025,941 | Oct 27, 2023, 04:15 PM |
BLATT LAWRENCE | Chief Executive Officer | Oct 25, 2023 | Option Exercise | $0.76 | 610,277 | 461,858 | 1,847,575 | Oct 27, 2023, 04:14 PM |
Scopa James Paul | Director | Oct 25, 2023 | Option Exercise | $0.76 | 183,083 | 138,557 | 183,083 | Oct 27, 2023, 04:13 PM |
Novo Holdings A/S | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 200,000 | 3,000,000 | 2,614,563 | Oct 22, 2020, 04:31 PM |
Woiwode Thomas | Director | Oct 20, 2020 | Buy | $15.00 | 200,000 | 3,000,000 | 862,444 | Oct 20, 2020, 05:00 PM |
Vivo Capital VIII, LLC | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 66,733 | 1,000,995 | 430,372 | Oct 20, 2020, 04:59 PM |
Vivo Capital VIII, LLC | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 483,267 | 7,249,005 | 3,116,658 | Oct 20, 2020, 04:59 PM |
Versant Venture Capital VI, L.P. | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 200,000 | 3,000,000 | 862,444 | Oct 20, 2020, 04:58 PM |
Owner | Relationship | Date | Value($) |
Nuechterlein Carole | Director | 10/25/2023 | 6,004,149 |
BLATT LAWRENCE | Chief Executive Officer | 10/25/2023 | 461,858 |
Scopa James Paul | Director | 10/25/2023 | 138,557 |
Novo Holdings A/S | 10% Owner | 10/20/2020 | 3,000,000 |
Woiwode Thomas | Director | 10/20/2020 | 3,000,000 |
Vivo Capital VIII, LLC | 10% Owner | 10/20/2020 | 1,000,995 |
Vivo Capital VIII, LLC | 10% Owner | 10/20/2020 | 7,249,005 |
Versant Venture Capital VI, L.P. | 10% Owner | 10/20/2020 | 3,000,000 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
VIVO CAPITAL, LLC | 3,547,030 | 0.19% | No change | Other |
HHLR ADVISORS, LTD. | 1,906,191 | 0.03% | -17.47% | Other |
BAKER BROS. ADVISORS LP | 2,076,400 | 0.02% | No change | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,223,278 | 0.00207% | Exited | Other |
RENAISSANCE TECHNOLOGIES LLC | 489,960 | 0.0005% | 52.46% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 321,044 | 0.00002% | 32.94% | Other |
BLACKROCK INC. | 296,139 | 0.00001% | -0.28% | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View